This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) To 2017: Global Analysis

Figure 8 1: A Healthcare 'Value-Net'

List of Tables:

Table 3 1: Global Molecular Diagnostics – Company Wise Market Share (Percent), 2010 – 2012Table 3 2: Global Molecular Diagnostics – Forecast for Company Wise Market Share (Percent), 2013 – 2017

Table 8 1: Molecular Platforms for Companion Diagnostics

Table 9 1: Detecting Respiratory Viruses in Upper and Lower Respiratory Tract Samples – Clinical Trials, 2012Table 9 2: Crizotinib Efficacy in Non-Small Cell Lung Cancer Patients with Anaplastic Lymphoma Kinase Translocation – Clinical Trials, 2012Table 9 3: A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus – Clinical Trials, 2012Table 9 4: Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler – Clinical Trials, 2012Table 9 5: A Two Arm, Multi-Centre Clinical Evaluation of the xTAG Respiratory Viral Panel v3 Test – Clinical Trials, 2013Table 9 6: Collecting and Storing Tissue Samples from Patients with Rare or Cutaneous Non-Hodgkin Lymphoma – Clinical Trials, 2012Table 9 7: Biopsies of Cancer Patients for Tumor Molecular Characterization – Clinical Trails, 2012Table 9 8: Daptomycin versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia – Clinical Trials, 2013Table 9 9: Collection of Tissue Samples for Cancer Research – Clinical Trials, 2012Table 9 10: Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma – Clinical Trials, 2012Table 9 11: Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia – Clinical Trials, 2012Table 9 12: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy, 2013Table 9 13: Congenital Muscle Disease Study of Patient and Family Reported Medical Information – Clinical Trials, 2013Table 9 14: Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer from Fine Needle Aspirates – Clinical Trials, 2013Table 9 15: Extending Molecular Responses with Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase – Clinical Trials, 2012Table 9 16: CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib – Clinical Trial, 2013Table 9 17: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile – Clinical Trials, 2013Table 9 18: Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients – Clinical Trials, 2012Table 9 19: Radotinib versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients – Clinical Trials, 2012Table 9 20: Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) – Clinical Trials, 2012

7 of 8

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs